mucosa (0-7%) [1] . Clinicopathological analysis of lymph node-positive mucosal cancers revealed that they were larger and more frequently of undifferentiated type, and that all had ulcerations or scars [2] . Therefore, patients with small differentiated mucosal cancers without ulcerative change have a low risk of lymph node metastasis, and are good candidates for local therapy such as endoscopic mucosal resection (EMR).
Introduction
Lymph node metastasis is uncommon in early gastric cancers (EGCs), especially in those confined to the
EMR strategies
EMR was performed by endoscopic snarectomy from 1978 to the middle of 1991, and subsequently with a submucosal saline injection, using a two-channel endoscope [7] .
All resected specimens were retrieved, pinned on hard Styrofoam plates, immersed in formalin, cut parallel into 2-mm serial sections, and subjected to histological examinations for evaluation of the extent of resection and risks of lymph node metastasis.
If lymph node metastasis appeared possible, as evidenced by submucosal invasion, lymphatic or venous invasion, ulcerative change, or positive submucosal margins, the patients were submitted to gastrectomy with lymph node dissection.
Follow-up endoscopy, for detection of local recurrence or metachronous multiple cancers, was scheduled at 1, 3, 6, and 12 months and then yearly after EMR.
Life prognosis investigation
The life prognoses of the patients were investigated by the Hospital Cancer Registry of Osaka Medical Center for Cancer and Cardiovascular Diseases, which is linked with the Osaka Cancer Registry, a population-based cancer registry covering Osaka Prefecture that has been operating since December 1962 [8] . Prognosis at the end of December 1998 was assessed by referral to residential registrations at municipality offices. Causes of death were confirmed by death certificates. For the outcomes of patients who moved away from Osaka Prefecture, we attempted to obtain details by questionnaires or telephone conversations with their families and referring physicians. Patients with unknown vital status were regarded as censored at the time when they were last known to be alive, and those who underwent gastrectomy were regarded as censored at the time of operation.
The mean estimated 5-and 10-year survival rates of the study subjects were calculated with a cohort survival rate table, provided by the Statistics and Survey Section of the National Cancer Center (http://www.ncc.go.jp/jp/ ncca/cohort01.html).
Informed consent
Possible risks; complications; anticipated results; and alternative options, such as surgery and no treatment, were explained to all patients, who gave their written informed consent. The study protocol was approved by the Ethics Committee of our institution.
Statistical analysis
Cumulative overall and disease-specific survivals were estimated using the Kaplan-Meier method. The computer software StatView version 5.0 (SAS Institute, Cary, NC, USA) was used for analysis.
Results
Vital status was unknown in 6 patients (4.6%), and 1 patient (0.76%) underwent surgical operation because cancer invasion to the muscularis mucosae had raised a suspicion of lymph node metastasis. Thus, 124 patients (95%) were completely followed-up, with a mean observation period of 58 months.
Two patients (1.5%) died of gastric cancer (Table 3 ) and 26 died of other causes. One patient, with a 20-mm protruding tumor, who underwent EMR died of gastric cancer 22 months after the EMR. In this patient, review of the stored pathological specimen revealed tumor invasion to the muscularis mucosae and lymphatic invasion despite the database describing the tumor as "completely resected". The other patient, who had a focal cancer in a hyperplastic polyp, showed no sign of local recurrence by surveillance endoscopy for 2 years, but then was lost to follow-up. The prognosis data from the Osaka Cancer Registry disclosed her death of gastric cancer 135 months after the EMR. The overall 5-and 10-year survival rates were 84% and 64%, respectively (Fig. 1) , and they were comparable to the mean estimated 5-and 10-year survival rates of 87% and 70%. The disease-specific 5-and 10-year survival rates were 99% and 99%, respectively (Fig. 2) .
Seven patients had synchronous double EGCs and one patient had triple EGCs. They were all treated by simultaneous EMR. During the observation period, metachronous multiple EGCs were found in nine patients, who were all treated by EMR. 
Discussion
This longterm follow-up study indicated that the prognosis of patients with small differentiated-type mucosal EGC (without ulcerative change) treated by EMR was excellent. Itoh et al. [9] showed that the 5-and 10-year postgastrectomy survival rates for patients with mucosal EGC were 96% and 92%. The overall survival rates in the current study were relatively low, but the disease-specific survival rates were comparable with those for gastrectomy. Our study subjects included elderly patients and those with complications in major organs, who are not good candidates for surgery. Thus, they may have died of other causes before death ensued from gastric cancer, resulting in overestimation of the disease-specific survival. To correct such bias, the prognosis of patients with EGC who have a low risk of surgery should be evaluated prospectively.
Concerning the good prognosis for EGC, some investigators claim that EGC represents a pseudocancer and rarely affects patients' life prognosis [10] . We have demonstrated that EGC, although it has a long natural history, would progress to an advanced stage and lead to death from gastric cancer [5] . The data derived from that investigation suggested that the 5-and 10-year survival rates of untreated patients with EGC who fulfilled the indications for EMR were 84% and 30%, respectively. Although those data are not truly comparable with those of the current study, we believe that EMR could reduce gastric cancer deaths in patients with EGC.
The efficacy of endoscopic surveillance should be considered. Multiple gastric cancers have been found in 2%-15% of gastric cancer patients [11, 12] , and are more frequent in EGC than in advanced cancer [13] . In contrast to gastrectomy, most of the gastric mucosa that may contain areas at high risk for developing EGCsuch as mucosa with atrophic gastritis and intestinal metaplasia -remain after EMR. Therefore, recognition of multiple cancers is one of the factors that would improve prognosis after EMR. In the present study, nine patients had metachronous multiple cancers, which were all treated by EMR. The patient who died of gastric cancer 135 months after EMR, because of a focal cancer in a hyperplastic polyp, was at no risk of lymph node or distant metastasis. We suspect that she died of a second primary cancer, although we could not obtain the relevant information on the circumstances of her death.
We experienced a patient with EGC who died of gastric cancer 22 months after complete EMR in whom lymphatic invasion was overlooked. Review of the stored pathological specimen revealed papillary adenocarcinoma invading the muscularis mucosae, with lymphatic invasion, despite the recorded data showing mucosal cancer. This case illustrates the importance of careful histological examination. In fact, among 145 patients who were endoscopically diagnosed as having EGC that fulfilled the indications for EMR and who received en-bloc resection, 13 had submucosal cancer and 1 had mucosal cancer with lymphatic invasion. In differentiated-type submucosal gastric cancer, lymphatic or venous invasion was the most significant determinant of lymph node metastasis, and papillary adenocarcinoma per se had an increased risk of lymph node metastasis [14] .
In conclusion, our longterm follow-up study clarified the efficacy of EMR for EGC. En bloc EMR ensured an excellent prognosis, and should be the first choice of treatment in patients with small differentiated mucosal EGC. Careful histological assessment, to determine the risk of lymph node metastasis, and longterm endoscopic surveillance for the detection of multiple cancers are important.
